RENX — Renalytix Income Statement
0.000.00%
Last trade - 00:00
- £15.35m
- £4.75m
- $3.40m
R2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 1.49 | 2.97 | 3.4 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.687 | 0.918 | 0.701 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.56 | 11.1 | 35.8 | 60.3 | 45.8 |
Operating Profit | -7.56 | -11.1 | -34.3 | -57.4 | -42.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.54 | -10.6 | -35.8 | -49.6 | -46.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.58 | -9.25 | -31 | -56.7 | -46.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.58 | -9.25 | -31 | -56.7 | -46.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.58 | -9.25 | -31 | -56.7 | -46.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.176 | -0.157 | -0.419 | -0.779 | -0.562 |